But, long-term studies have also raised concerns about side effects like pancreatitis and gallbladder disease
NEJM has published Phase II data for retatrutide (Jastreboff et al, June 2023, doi 10.1056/NEJMoa2301972) and the SURPASS and SURMOUNT programmes for tirzepatide
Afamelanotide, via Scenesse, benefits from a well-characterized safety profile in EPP therapeutic use: controlled cutaneous hyperpigmentation, rare digestive effects, no major cardiovascular signal
While injectables like Zepbound and Wegovy show higher average weight loss percentages, oral choices provide the convenience of a daily regimen
Where available, fold differences were calculated from total curcumin plasma levels, and from the AUC for the longest defined time period
doi:10.1007/s00380-004-0822-4